Search Results - amy+fulton

2 Results

Sort By:

Value PropositionFirst-in-Class Targeting of a Novel Oncogenic Ion Channel: Inhibiting KCNK9 represents a new therapeutic modality in cancers where traditional approachesTumor-Specific Overexpression Enables Selectivity: KCNK9 is overexpressed in various tumors (e.g., breast, gastric, lung) but has limited expression in most normal tissuesPro-Apoptotic...

Published: 6/27/2025 | Inventor(s): John Laterra, Amy Fulton

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer, Clinical and Disease Specializations > Oncology > Gastric Cancer, Technology Classifications > Therapeutic Modalities > Antibodies

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 6/26/2025 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer